β-Blockers in sepsis: Protocol for a systematic review and meta-analysis of randomised control trials

BMJ Open

Volumn 6, Issue 6, 2016, Pages

  Duan, Erick H ^a   Oczkowski, Simon J W ^a   Belley Cote, Emilie ^a,b,c   Whitlock, Richard ^a,b   Lamontagne, Francois ^c,d   Devereaux, Phillip J ^a,b   Cook, Deborah J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

beta blockers; sepsis; systematic review

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HEART INDEX; HEART RATE; HUMAN; LENGTH OF STAY; MEAN ARTERIAL PRESSURE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; RISK FACTOR; SEPSIS; SYSTEMATIC REVIEW; METHODOLOGY;

ADRENERGIC BETA-ANTAGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEPSIS;

EID: 84976623164     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-012466     Document Type: Article

References (27)

1. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53
2. Kaukonen KM, Bailey M, Suzuki S, et al. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311: 1308-16
3. Gaieski DF, Edwards JM, Kallan MJ, et al. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013; 41: 1167-74
4. Stevenson EK, Rubenstein AR, Radin GT, et al. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014; 42: 625-31
5. Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 2009; 24: 293-316
6. de Montmollin E, Aboab J, Mansart A, et al. Bench-to-bedside review: beta-adrenergic modulation in sepsis. Crit Care 2009; 13: 230
7. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483-90
8. Levy B, Gibot S, Franck P, et al. Relation between muscle Na+K+ ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 2005; 365: 871-5
9. Werdan K, Schmidt H, Ebelt H, et al. Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 2009; 87: 266-74
10. Zanotti-Cavazzoni SL, Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 2009; 15: 392-7
11. Chacko CJ, Gopal S. Systematic review of use of β-blockers in sepsis. J Anaesthesiol Clin Pharmacol 2015; 31: 460-5
12. Sanfilippo F, Santonocito C, Morelli A, et al. Beta-blocker use in severe sepsis and septic shock: a systematic review. Curr Med Res Opin 2015; 31: 1817-25
13. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003; 107: 1570-5
14. Norbury WB, Jeschke MG, Herndon DN. Metabolism modulators in sepsis: propranolol. Crit Care Med 2007; 35: S616-20
15. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001; 345: 1223-9
16. Hargrove DM, Bagby GJ, Lang CH. Adrenergic blockade prevents endotoxin-induced increases in glucose metabolism. Am J Physiol 1988; 255(5 Pt 1): E629-35
17. Devereaux PJ, Yang H, Yusuf S, et al, POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839-47
18. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10
19. Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration?s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928
20. Akl EA, Sun X, Busse JW, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 2012; 65: 262-7
21. Wiest D. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet 1995; 28: 190-202
22. Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002-2
23. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet 1997; 350: 1182
24. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta-analyses with binary outcomes. Stat Med 2008; 27: 746-63
25. Guyatt GH, Oxman AD, Schünemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64: 380-2
26. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015; 349: g7647
27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264-9, W64